Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. More Details
Flawless balance sheet and undervalued.
Share Price & News
How has Ovid Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OVID is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: OVID's weekly volatility has decreased from 13% to 6% over the past year.
7 Day Return
1 Year Return
Return vs Industry: OVID underperformed the US Biotechs industry which returned 23.1% over the past year.
Return vs Market: OVID underperformed the US Market which returned 37.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Ovid Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StOvid Therapeutics' (NASDAQ:OVID) Shareholders Are Down 61% On Their Shares
3 months ago | Simply Wall StOvid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability
4 months ago | Simply Wall StAnalysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts
Is Ovid Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: OVID ($3.73) is trading below our estimate of fair value ($49.84)
Significantly Below Fair Value: OVID is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: OVID is good value based on its PE Ratio (2.1x) compared to the US Biotechs industry average (26.2x).
PE vs Market: OVID is good value based on its PE Ratio (2.1x) compared to the US market (18.4x).
Price to Earnings Growth Ratio
PEG Ratio: OVID's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: OVID is good value based on its PB Ratio (1.1x) compared to the US Biotechs industry average (2.8x).
How is Ovid Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OVID's earnings are forecast to decline over the next 3 years (-60.7% per year).
Earnings vs Market: OVID's earnings are forecast to decline over the next 3 years (-60.7% per year).
High Growth Earnings: OVID's earnings are forecast to decline over the next 3 years.
Revenue vs Market: OVID's revenue is expected to decline over the next 3 years (-44.1% per year).
High Growth Revenue: OVID's revenue is forecast to decline over the next 3 years (-44.1% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: OVID is forecast to be unprofitable in 3 years.
How has Ovid Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OVID has high quality earnings.
Growing Profit Margin: OVID became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: OVID has become profitable over the past 5 years, growing earnings by 4% per year.
Accelerating Growth: OVID has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: OVID has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: OVID's Return on Equity (52%) is considered outstanding.
How is Ovid Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: OVID's short term assets ($236.7M) exceed its short term liabilities ($16.3M).
Long Term Liabilities: OVID has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: OVID is debt free.
Reducing Debt: OVID has not had any debt for past 5 years.
Debt Coverage: OVID has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: OVID has no debt, therefore coverage of interest payments is not a concern.
What is Ovid Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OVID's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OVID's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OVID's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OVID's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OVID's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jeremy Levin (68 yo)
Dr. Jeremy Max Levin, BA Zoology, DPhil, MB BChir, has been the Chief Executive Officer of Ovid Therapeutics Inc. since March 2015 and serves as its Executive Director. From 1996 to 2000, Dr. Levin has exp...
CEO Compensation Analysis
Compensation vs Market: Jeremy's total compensation ($USD2.14M) is above average for companies of similar size in the US market ($USD1.09M).
Compensation vs Earnings: Jeremy's compensation has been consistent with company performance over the past year.
Experienced Management: OVID's management team is considered experienced (3.8 years average tenure).
Experienced Board: OVID's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.8%.
Ovid Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Ovid Therapeutics Inc.
- Ticker: OVID
- Exchange: NasdaqGS
- Founded: 2014
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$254.955m
- Shares outstanding: 67.81m
- Website: https://www.ovidrx.com
Number of Employees
- Ovid Therapeutics Inc.
- 1460 Broadway
- Suite 15021
- New York
- New York
- United States
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candida...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/31 02:12|
|End of Day Share Price||2021/07/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.